http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
-
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
-
Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
-
Mainz Biomed (MYNZ) Reports H1 Results, Provides Corporate Update
-
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
-
Mainz Biomed (MYNZ) Announces Live Launch of ColoAlert with Marylebone Laboratory in the UK
-
Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom
-
Mainz Biomed (MYNZ) Announces Collaboration with Fugene Genetics in Israel
-
Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
-
Mainz Biomed (MYNZ) Announces $50M in New Funding
-
Mainz Biomed Secures up to $50M in New Funding
-
Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain
-
Mainz Biomed (MYNZ) Partners with Bioclinica in Romania
-
Mainz Biomed Expands into Romania Through Partnership with Bioclinica
-
Mainz Biomed Expands Commercial Footprint into Poland
-
Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper
-
Mainz Biomed (MYNZ) Reports Q1 Revenue of $250K, EPS of ($0.45)
-
Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update
-
Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert
-
Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab Partners
-
Mainz Biomed to Participate in Digestive Disease Week 2023
-
Mainz Biomed to Participate in Digestive Disease Week 2023
-
Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany
-
Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany
-
Mainz Biomed (MYNZ) Partners with the Instituto de Microecologia to Expand ColoAlert Commercialization in Spain and Portugal
-
Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal
-
Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal
-
Mainz Biomed (MYNZ) Reports FY22 Results
-
Mainz Biomed Provides Full Year 2022 Financial Results
-
Mainz Biomed Provides Full Year 2022 Financial Results
-
Mainz Biomed (MYNZ) Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
-
Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
-
Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
-
Mainz Biomed (MYNZ) Reports Positive Results from Feasibility Study Evaluating its Portfolio of mRNA Biomarkers
-
Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal Adenomas
-
Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal Adenomas
-
Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23
-
Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23
-
Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany
-
Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany
-
Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection
-
Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection
-
Mainz Biomed to Appear on ClearThink IR’s Virtual Live Event on Wednesday, March 1, 2023 at 12 Noon ET
-
Mainz Biomed (MYNZ) Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program
-
Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program
-
Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program
-
Mainz Biomed (MYNZ) Expands Into Spain and UK
-
Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK
-
Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK
-
Mainz Biomed (MYNZ) Launches Corporate Health Program in Germany for ColoAlert

